MDxHealth SA (NASDAQ:MDXH) Receives $7.75 Average Price Target from Analysts

MDxHealth SA (NASDAQ:MDXH) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7.75.

MDXH has been the subject of several analyst reports. BTIG Research restated a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a report on Tuesday, December 23rd. Lake Street Capital raised their target price on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. TD Cowen increased their price target on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th.

Institutional Investors Weigh In On MDxHealth

Several hedge funds have recently modified their holdings of MDXH. Kennedy Capital Management LLC bought a new position in shares of MDxHealth during the third quarter valued at approximately $1,826,000. FreeGulliver LLC boosted its position in MDxHealth by 104.7% during the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after acquiring an additional 129,348 shares in the last quarter. Mink Brook Asset Management LLC bought a new stake in MDxHealth during the 3rd quarter valued at $743,000. Panoramic Capital LLC purchased a new position in shares of MDxHealth in the 3rd quarter valued at $721,000. Finally, Russell Investments Group Ltd. bought a new position in shares of MDxHealth in the 3rd quarter worth $461,000.

MDxHealth Stock Performance

Shares of MDxHealth stock opened at $3.43 on Friday. The stock has a market cap of $162.20 million, a price-to-earnings ratio of -5.36 and a beta of 1.62. The stock has a 50 day moving average price of $3.77 and a 200-day moving average price of $3.43. MDxHealth has a one year low of $1.35 and a one year high of $5.33.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. Sell-side analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.